Abstract
Background Epstein Barr Virus (EBV) infection of B cells is now understood to be one of the triggering events for the development of Multiple Sclerosis (MS), a progressive immune-mediated disease of the central nervous system. EBV infection is also linked to expression of Human endogenous retroviruses (HERVs) of the HERV-W group, a further risk factor for the development of MS (Ocrelizumab is a high-potency disease-modifying treatment (DMT) for MS, which depletes B cells by targeting CD20.
Objectives We studied the effects of ocrelizumab on gene expression in peripheral blood mononuclear cells (PBMC) from paired samples from 20 patients taken prior to and 6 months after beginning Ocrelizumab therapy. We hypothesised that EBV and HERV-W loads would be lower in post-treatment samples.
Methods Samples were collected in Paxgene tubes, subject to RNA extraction and Illumina paired end short read mRNA sequencing with mapping of sequence reads to the human genome using Salmon and Differential Gene expression compared with DeSeq2. Mapping was also performed separately to the HERV-D database of HERV sequences and the EBV reference sequence.
Results Patient samples were more strongly clustered by individual rather than disease type (relapsing/remitting or primary progressive), treatment (pre and post), age, or sex. Fourteen genes, all clearly linked to B cell function were significantly down regulated in the post treatment samples. Interestingly only one pre-treatment sample had detectable EBV RNA and there were no significant differences in HERV expression (of any group) between pre- and post-treatment samples.
Conclusions While EBV and HERV expression are clearly linked to triggering MS pathogenesis, it does not appear that high level expression of these viruses is a part of the ongoing disease process or that changes in virus load are associated with Ocrelizumab treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for this project was provided by Roche UK who played no role in study design, execution, analysis or publication. RTan received support from the UK MRC (CARP MR/T024402/1). The authors declare no other interests.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was granted by the University of Nottingham, Faculty of Medicine and Health Sciences Research and Ethical Committee number: MREC 08/H0408/167.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Radu.tanasescu{at}nottingham.ac.uk
Bruno.gran{at}nottingham.ac.uk
C.ShannonLowe{at}bham.ac.uk
Data Availability
RNAseq reads are available at Genbank Bioproject PRJNA1001267 Accession numbers SRR25490470-SRR25490511
